Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Public ClinicalTrials.gov record NCT05948475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
Study identification
- NCT ID
- NCT05948475
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- Tinengotinib 8 mg Drug
- Tinengotinib 10 mg Drug
- Physician's Choice Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2023
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Jul 5, 2026
2023 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center | Santa Monica | California | 90401 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| The University of Kansas Cancer Center | Westwood, Los Angeles | California | 90024 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| The University of Chicago Hospitals | Chicago | Illinois | 60601 | — |
| UMass Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| University of Michigan | Ann Arbor | Michigan | 48103 | — |
| Henry Ford | Detroit | Michigan | 48201 | — |
| University of Minnesota- Masonic Cancer Center, M Health Fairview | Minneapolis | Minnesota | 55455 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Messino Cancer Centers | Asheville | North Carolina | 28806 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Tennessee Oncology- Nashville | Nashville | Tennessee | 37203 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75201 | — |
| Texas Oncology-Sammons Cancer Center | Dallas | Texas | 75246 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77002 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05948475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05948475 live on ClinicalTrials.gov.